The association of diabetes mellitus treated with oral antidiabetic drugs and insulin with mortality after transcatheter valve implantation: a 3-year follow-up of the TAVIK registry

Table 4 Multivariate Cox regression analysis at 1 and 3 years

	1 year		3 years
	HR (95% CI)	p-value	HR (95% CI)	p-value
Male gender	1.14 (0.90–1.45)	0.274	0.90 (0.76–1.06)	0.217
Age	1.02 (1.002–1.04)	0.031	1.03 (1.01–1.04)	< 0.001
Diabetes
Orally treated	0.89 (0.67–1.19)	0.452	0.99 (0.82–1.21)	0.935
Insulin treated	1.29 (0.97–1.72)	0.084	1.21 (0.98–1.49)	0.079
EF	0.98 (0.98–0.99)	< 0.001	0.99 (0.99–1.0)	0.001
PAD	1.44 (1.10–1.90)	0.008	1.32 (1.09–1.60)	0.005
Carotid stenosis	1.02 (0.77–1.35)	0.904	0.99 (0.81–1.20)	0.902
COPD	1.37 (1.003–1.87)	0.048	1.41 (1.14–1.74)	0.002
Previous valve surgery	1.13 (0.65–1.94)	0.667	0.97 (0.65–1.46)	0.898
Major neurological deficits	1.08 (0.77–1.51)	0.644	1.13 (0.89–1.43)	0.302
Pulmonary hypertension	1.42 (1.11–1.81)	0.005	1.35 (1.13–1.61)	0.001
Previous MI	1.18 (0.86–1.60)	0.308	1.08 (0.86–1.35)	0.535
Previous CABG	1.13 (0.83–1.55)	0.439	1.40 (1.13–1.73)	0.002
Mitral valve disease	1.26 (0.95–1.68)	0.104	1.07 (0.87–1.33)	0.525
Frailty	1.77 (1.41–2.23)	< 0.001	1.77 (1.51–2.08)	< 0.001
Chronic renal failure	2.65 (1.89–3.73)	< 0.001	2.39 (1.85–3.09)	< 0.001
CAD	0.99 (0.77–1.28)	0.963	1.07 (0.90–1.29)	0.397

CABG coronary artery bypass graft, CAD coronary artery disease, LVEF left ventricular ejection fraction, MI myocardial infarction, PAD peripheral artery disease, COPD chronic obstructive pulmonary disease

ISSN: 1475-2840